PharmaSGP Holding SE: PharmaSGP convenes extraordinary general meeting to resolve on Squeeze-out

Corporate News

Gräfelfing, September 22, 2025 – As already announced in the ad hoc announcement by PharmaSGP Holding SE on July 24, 2025, FUTRUE GmbH informed PharmaSGP Holding SE on July 24, 2025 that it owns more than 95% of the shares in PharmaSGP Holding SE within the meaning of Section 327a of the German Stock Corporation Act (AktG) and that, pursuant to Section 327a para. 1 AktG, the general meeting of PharmaSGP Holding SE should resolve to transfer the shares of the remaining shareholders of PharmaSGP Holding SE to FUTRUE GmbH in return for an appropriate cash compensation (so-called squeeze-out).

Meanwhile, FUTRUE GmbH specified its request after the necessary valuation had been conducted, stating the cash compensation it has determined. This cash compensation amounts to EUR 29.33 for each no-par value bearer share in PharmaSGP Holding SE.

Based on this specified request, PharmaSGP Holding SE has today convened an extraordinary general meeting for October 31, 2025, which is to resolve on the transfer of the shares of the remaining shareholders to FUTRUE GmbH in return for the aforementioned appropriate cash compensation. Further information and documents relating to the extraordinary general meeting are available on the company's website.

The squeeze-out will take effect subject to the approval of the general meeting and the registration of the transfer resolution with the commercial register of PharmaSGP Holding SE.

ABOUT PHARMASGP HOLDING SE

PharmaSGP is a leading consumer health company with a diversified portfolio of over-the-counter (OTC) pharmaceuticals and other healthcare products that are marketed with a focus on the pharmacy distribution channel. These products are mostly based on natural active pharmaceutical ingredients with documented efficacy and few known side effects.

The Company’s core brands cover chronic indications, including rheumatic pain, nerve pain and other age-related ailments. In Germany, PharmaSGP is the market leader for systemic chemical-free pain remedies with its brand families RubaXX® for rheumatic pain and Restaxil® for neuralgic pain. Furthermore, PharmaSGP also offers leading products against sexual weakness and vertigo symptoms. Since introducing the first product from the current product portfolio in 2012, PharmaSGP has successfully established its business model in other European countries, including Austria, Italy, Belgium, Spain and France. In September 2021, the product portfolio was expanded by the brands Baldriparan®, Formigran®, Spalt® and Kamol®, thus also strengthening or developing the indications pain and sleep disorder. The sales territory was expanded to include Switzerland and Eastern Europe. In 2024, PharmaSGP generated revenues of EUR 118.8 million at an adjusted EBITDA margin of 31.3%.

Mynaric Completes StaRUG Process and Secures Access to Long-Term Funding

Corporate News

MUNICH – August 19, 2025 – Mynaric AG, a leading provider of industrialized, cost-effective, and scalable laser communications products, today announced the successful completion of its financial restructuring under the German Corporate Stabilization and Restructuring Act (StaRUG). With this milestone, Mynaric has secured access to long-term funding and a strengthened financial foundation through its new principal shareholder, JVF-Holding GmbH.

The court-approved restructuring plan significantly reduces the company’s debt burden and provides Mynaric with the financial flexibility to deliver on its production strategy to meet the increasing demand for secure, high-speed laser communication solutions across aerospace and defense markets.

“This marks a pivotal moment for Mynaric,” said Andreas Reif, Chief Restructuring Officer of Mynaric. “With the StaRUG process behind us and strong financial backing from our principal shareholder and lender, we are well-positioned to scale our operations and continue serving our customers with innovative and mission-critical technology.”

Throughout the process, Mynaric maintained uninterrupted operations, safeguarded its core capabilities, and remained fully committed to its customers and partners.

“This milestone ensures that we can continue to innovate at the pace our customers and partners expect,” said Joachim Horwath, Chief Technology Officer of Mynaric. “With a stable foundation and strong support from our principal shareholder and lender, as well as our suppliers, we are doubling down on advancing our product portfolio, scaling production, and delivering cutting-edge laser communication technology that defines the next generation of secure, high-speed connectivity.”

About Mynaric

Mynaric is leading the industrial revolution of laser communications by producing optical communications terminals for air, space and mobile applications. Laser communication networks provide connectivity from the sky, allowing for ultra-high data rates and secure, long-distance data transmission between moving objects for wireless terrestrial, mobility, airborne- and space-based applications. The company is headquartered in Munich, Germany, with additional operations in Los Angeles, California.

For more information, visit mynaric.com.

ENCAVIS AG: Merger squeeze-out completed

Corporate News

Hamburg, 12 September 2025 – The exclusion of minority shareholders by means of a merger squeeze-out, as resolved by the ENCAVIS AG Annual General Meeting on 16 July 2025, took effect upon entry in the commercial register of the registered office of the principal shareholder, Elbe BidCo AG, as the acquiring legal entity on 10 September 2025. All shares held by minority shareholders have been transferred to the principal shareholder, a holding company controlled by investment funds, vehicles and accounts advised and managed by Kohlberg Kravis Roberts & Co. L.P. (KKR). Minority shareholders will receive a cash settlement of EUR 17.23 per share held in ENCAVIS AG from the principal shareholder. Further details will be announced by the principal shareholder.

About ENCAVIS

Encavis is one of Europe’s leading producers of electricity from Renewable Energy. The company operates a broadly diversified portfolio of onshore wind farms, ground-mounted solar parks, and battery storage systems across 13 European countries — including Germany, Italy, Spain, Denmark, and the Netherlands. In addition, Encavis offers institutional investors attractive opportunities to participate in Renewable Energy assets. Its subsidiary, Stern Energy, complements the service portfolio as a Europe-wide specialist in technical services for photovoltaic systems.

With a total installed capacity of around 4 gigawatts, Encavis makes a significant contribution to sustainable energy supply and the achievement of Europe’s climate goals.

Further information can be found at www.encavis.com.

_____________

Editor's note:

The appropriateness of the cash settlement offered will be reviewed in appraisal proceedings. For further information: kanzlei@anlageanwalt.de